148 related articles for article (PubMed ID: 8429345)
1. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation.
John E; Thakur ML; DeFulvio J; McDevitt MR; Damjanov I
J Nucl Med; 1993 Feb; 34(2):260-7. PubMed ID: 8429345
[TBL] [Abstract][Full Text] [Related]
2. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
Visser GW; Gerretsen M; Herscheid JD; Snow GB; van Dongen G
J Nucl Med; 1993 Nov; 34(11):1953-63. PubMed ID: 8229241
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
Breitz HB; Weiden PL; Vanderheyden JL; Appelbaum JW; Bjorn MJ; Fer MF; Wolf SB; Ratliff BA; Seiler CA; Foisie DC
J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
[TBL] [Abstract][Full Text] [Related]
5. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
[TBL] [Abstract][Full Text] [Related]
6. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies.
Griffiths GL; Goldenberg DM; Knapp FF; Callahan AP; Chang CH; Hansen HJ
Cancer Res; 1991 Sep; 51(17):4594-602. PubMed ID: 1873804
[TBL] [Abstract][Full Text] [Related]
7. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
9. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection.
Dadachova E; Bryan RA; Huang X; Ortiz G; Moadel T; Casadevall A
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5629s-5635s. PubMed ID: 17875799
[TBL] [Abstract][Full Text] [Related]
11. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99m-labeled monoclonal antibodies for immunoscintigraphy. Simplified preparation and evaluation.
Thakur ML; DeFulvio JD
J Immunol Methods; 1991 Mar; 137(2):217-24. PubMed ID: 2013698
[TBL] [Abstract][Full Text] [Related]
14. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site.
Ogawa K; Kawashima H; Kinuya S; Shiba K; Onoguchi M; Kimura H; Hashimoto K; Odani A; Saji H
Ann Nucl Med; 2009 Dec; 23(10):843-8. PubMed ID: 19921351
[TBL] [Abstract][Full Text] [Related]
16. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
[TBL] [Abstract][Full Text] [Related]
18. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
19. Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.
Kinuya S; Yokoyama K; Izumo M; Sorita T; Obata T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Cancer Lett; 2005 Feb; 219(1):41-8. PubMed ID: 15694663
[TBL] [Abstract][Full Text] [Related]
20. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
